Actividad de ciprofloxacino 500mg tabletas de formulaciones genérica y comercial frente a escherichia coli y staphylococcus aureus, y su equivalencia química con respecto al medicamento innovador”
Ortega Cueva, Lila Paola
Trujillo Rodríguez, Walter Linderberh
MetadatosMostrar el registro completo del ítem
This research was conducted to determine the antibacterial activity of Ciprofloxacin 500 mg tablets of RANBAXY, NATURGEN and FARMINDUSTRIA Laboratories with respect to benchmark (BAYER) against Escherichia coli and Staphylococcus aureus. In turn, made the identification and quantification of Ciprofloxacin in pharmaceutical formulations contained laboratories mentioned using spectrophotometric UV, method the USP method XXI. Ciprofloxacin concentrations RANBAXY lab found was 519.26 mg (103.85% ± 0.7128), 521.30 mg NATURGEN (104.26% ± 0.8486) and 519.53 mg FARMINDUSTRIA (103.53% ± 0.1337), with a relative standard deviation (RSD) of less than 2 %. Fulfilling the all cases with the range allowed by the USP XX-NFXV (85% - 115%). Antibacterial activity was determined by seeding in five petri dishes of Escherichia. coli and five Petri dishes of Staphylococcus aureus, which was used for the diffusion technique in Mueller Hinton agar by Kirby Bauer method. For the data treatment was applied variance analysis, with a significance level of 5%, we found that the generic and commercial laboratories FARMINDUSTRIA, NATURGEN and RANBAXY have no significant difference in the antibacterial effect with respect to the reference drug (BAYER).